

SKINVISIBLE INC
Form 10-Q
November 19, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended **September 30, 2012**

Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _____ to _____

Commission File Number: **000-25911**

Skinvisible, Inc.

(Exact name of Registrant as specified in its charter)

Nevada 88-0344219
(State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

6320 South Sandhill Road, Suite 10, Las Vegas, NV 89120
(Address of principal executive offices)

702.433.7154
(Registrant's telephone number)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days

Yes No

Edgar Filing: SKINVISIBLE INC - Form 10-Q

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer Accelerated filer Non-accelerated filer
 Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No

State the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:
108,736,909 common shares as of September 30, 2012.

Table of Contents

TABLE OF CONTENTS

Page

PART I – FINANCIAL INFORMATION

| | |
|--|----|
| Item 1: <u>Financial Statements</u> | 3 |
| Item 2: <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | 4 |
| Item 3: <u>Quantitative and Qualitative Disclosures About Market Risk</u> | 10 |
| Item 4: <u>Controls and Procedures</u> | 10 |

PART II – OTHER INFORMATION

| | |
|--|----|
| Item 1: <u>Legal Proceedings</u> | 11 |
| Item 1A: <u>Risk Factors</u> | 12 |
| Item 2: <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 12 |
| Item 3: <u>Defaults Upon Senior Securities</u> | 12 |
| Item 4: <u>Mine Safety Disclosure</u> | 12 |
| Item 5: <u>Other Information</u> | 12 |
| Item 6: <u>Exhibits</u> | 12 |

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Our consolidated financial statements included in this Form 10-Q are as follows:

- F-1 Consolidated Balance Sheets as of September 30, 2012 (unaudited) and December 31, 2011 (audited):
- F-2 Consolidated Statements of Operations for the three and nine months ended September 30, 2012 and 2011 (unaudited):
- F-3 Consolidated Statements of Cash Flow for the nine months ended September 30, 2012 and 2011 (unaudited):
- F-4 Notes to Consolidated Financial Statements.

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended September 30, 2012 are not necessarily indicative of the results that can be expected for the full year.

Table of Contents

SKINVISIBLE, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

| | September 30, 2012 | December 31, 2011 (Restated) |
|--|-----------------------|------------------------------------|
| ASSETS | | |
| Current assets | | |
| Cash | \$67,143 | \$1,218 |
| Accounts receivable | 10,000 | 1,105 |
| Inventory | 5,955 | 14,953 |
| Due from related party | 1,145 | 1,145 |
| Prepaid expense and other current assets | 18,304 | 8,613 |
| Total current assets | 102,547 | 27,034 |
| Fixed assets, net of accumulated depreciation of \$330,994 and \$330,001, respectively | 4,774 | 5,717 |
| Intangible and other assets: | | |
| Patents and trademarks, net of accumulated amortization of \$205,670 and \$162,621, respectively | 277,150 | 264,166 |
| Total assets | \$384,471 | \$296,917 |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | | |
| Current liabilities | | |
| Accounts payable and accrued liabilities | \$719,527 | \$623,972 |
| Accrued interest payable | 23,174 | — |
| Loans from related party | | 12,400 |
| Loans payable | 22,661 | 27,661 |
| Convertible notes payable, net of unamortized debt discount of \$89,868 and \$-0-, respectively | 383,298 | 62,475 |
| Convertible notes payable related party, net of unamortized discount of \$979,812 and \$1,145,867, respectively | 468,288 | 84,789 |
| Unearned revenue | 179,792 | 229,792 |
| Total current liabilities | 1,796,740 | 1,041,089 |
| Total liabilities | 1,796,740 | 1,041,089 |
| Stockholders' deficit | | |
| Common stock; \$0.001 par value; 200,000,000 shares authorized 108,736,909 and 106,592,159 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively | 108,738 | 106,594 |
| Additional paid-in capital | 20,611,698 | 20,268,177 |
| Accumulated deficit | (22,132,705) | (21,118,943) |
| Total stockholders' deficit | (1,412,269) | (744,172) |

| | | |
|---|-----------|-----------|
| Total liabilities and stockholders' deficit | \$384,471 | \$296,917 |
|---|-----------|-----------|

See Accompanying Notes to Consolidated Financial Statements.

F-1

Table of Contents

SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

| | Three months ended | | Nine months ended | |
|--|-----------------------|-----------------------|-----------------------|-----------------------|
| | September 30, 2012 | September 30, 2011 | September 30, 2012 | September 30, 2011 |
| Revenues | \$22,920 | \$31,232 | \$83,548 | \$177,502 |
| Cost of revenues | — | 328 | 1,944 | 766 |
| Gross profit | 22,920 | 30,904 | 81,604 | 176,736 |
| Operating expenses | | | | |
| Depreciation and amortization | 8,068 | 12,686 | 43,982 | 40,129 |
| Selling general and administrative | 316,856 | 352,683 | 996,189 | 854,896 |
| Total operating expenses | 324,924 | 365,369 | 1,040,171 | 895,025 |
| Loss from operations | (302,004) | (334,465) | (958,567) | (718,289) |
| Other income and (expense) | | | | |
| Other income | 25,000 | — | 25,000 | — |
| Interest expense | (11,866) | (27,156) | (81,886) | (70,731) |
| Gain on extinguishment of Debt | (36) | — | 1,691 | — |
| Total other expense | 13,098 | (27,156) | (55,195) | (70,731) |
| Net loss | \$(288,906) | \$(361,621) | \$(1,013,762) | \$(789,020) |
| Basic loss per common share | \$(0.00) | \$(0.00) | \$(0.01) | \$(0.01) |
| Basic weighted average common shares outstanding | 105,073,960 | 102,554,925 | 102,694,597 | 101,125,757 |

See Accompanying Notes to Consolidated Financial Statements.

F-2

Table of Contents

SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

| | Nine months ended | |
|---|-----------------------|-----------------------|
| | September 30, 2012 | September 30, 2011 |
| Cash flows from operating activities: | | |
| Net loss | \$(1,013,762) | \$(426,999) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | |
| Depreciation and amortization | 43,982 | 27,443 |
| Stock based compensation | — | 104,100 |
| Amortization of debt discount | 432,602 | 277,487 |
| Stock issued for conversion of accounts payable | | — |
| Debt paid with common stock | 78,361 | — |
| Accrued expenses converted to notes | 223,868 | — |
| Gain on extinguishment of debt | (1,691) | — |
| Changes in operating assets and liabilities: | | |
| Decrease in inventory | 8,998 | 438 |
| Increase in accounts receivable | (8,895) | (210,000) |
| Increase in prepaid expenses and other current assets | (9,691) | (27,961) |
| Increase in accounts payable and accrued liabilities | 97,283 | 12,046 |
| Increase in accrued interest | 23,174 | 40,978 |
| Increase (decrease) in unearned revenue | (50,000) | 141,977 |
| Net cash used in operating activities | (175,771) | (60,491) |
| Cash flows from investing activities: | | |
| Purchase of fixed assets and intangible assets | (56,023) | (51,107) |
| Net cash used in investing activities | (56,023) | (51,107) |
| Cash flows from financing activities: | | |
| Proceeds from issuance of stock | — | 78,000 |
| Proceeds from, net of payments to, related parties for loans | (2,681) | 6,647 |
| Proceeds from convertible notes payable | 312,900 | — |
| Payments on convertible notes payable | (7,500) | — |
| Proceeds from loans | — | 25,200 |
| Payments on loans | (5,000) | — |
| Net cash provided by financing activities | 297,719 | 109,847 |
| Net change in cash | 65,925 | (1,751) |
| Cash, beginning of period | 1,218 | 2,481 |
| Cash, end of period | \$67,143 | \$730 |

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Non-cash investing and financing activities:

| | | |
|--|-----------|----------|
| Loan payable converted to convertible loan | \$(9,719 |) \$— |
| Common stock issued on conversion of debts | \$78,361 | \$56,056 |
| Beneficial conversion feature | \$326,510 | \$— |

See Accompanying Notes to Consolidated Financial Statements.

F-3

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES

Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

History – Skinvisible, Inc. (referred to as the “Company”) was incorporated in Nevada on March 6, 1998 under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

Skinvisible, Inc. together with its subsidiary shall herein be collectively referred to as the “Company”.

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of \$22,132,705 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiary. All significant intercompany balances and transactions have been eliminated.

Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents.

Fair Value of Financial Instruments

The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The three levels of the fair value hierarchy are described below:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Revenue recognition

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that

reflects management's best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2012 and December 31, 2011, the Company had not recorded a reserve for doubtful accounts.

Inventory – Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.

Goodwill and intangible assets – The Company follows Financial Accounting Standard Board's (FASB) Codification Topic 350-10 ("ASC 350-10"), "*Intangibles – Goodwill and Other*". According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, "*Income Taxes*", which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

F-5

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “*Compensation-Stock Compensation*”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to a Employee Stock Purchase Plan based on the estimated fair values.

Stock based compensation expense recognized under ASC 718-10 for the nine months ended September 30, 2012 and 2011 totaled \$0 and \$135,000 respectively.

Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “*Earnings Per Share*”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

Restatement

Upon completion of the Company’s September 30, 2012 financial statements, accounting errors were discovered that required the restatement of amounts previously reported as of December 31, 2011. The Company’s financial statements as of December 31, 2011 included amounts related to convertible note debt discount that were improperly calculated

The following is a summary of the impact of these restatements on the Company’s Consolidated Balance Sheet at December 31, 2011:

| | December 31, 2011 | | |
|--|------------------------|------------------|-------------|
| | As previously reported | Error correction | As restated |
| Convertible notes payable related party, net of unamortized discount | \$531,810 | \$(447,021)(a) | \$84,789 |
| Total current liabilities | \$1,488,110 | \$(447,021)(a) | \$1,041,089 |

Edgar Filing: SKINVISIBLE INC - Form 10-Q

| | | | |
|-----------------------------|----------------|------------|-------------------|
| Additional paid-in capital | \$ 19,821,156 | \$ 447,021 | (a) \$ 20,268,177 |
| Total stockholders' deficit | \$(1,191,193) | \$ 447,021 | (a) \$(744,172) |

(a) To correct errors in debt discount of convertible notes payable related party.

The following is a summary of the impact of these restatements on the Company's Consolidated Statements of Equity for the fiscal year ended December 31, 2011:

| | December 31, 2011 | | |
|---|------------------------|------------------|-------------------|
| | As previously reported | Error correction | As restated |
| Balance Additional Paid-in Capital | \$ 19,821,156 | \$ 447,021 | (a) \$ 20,268,177 |
| Balance September 30, 2011 - Total Stockholder's Equity | \$(1,360,485) | \$ 447,021 | (a) \$(744,172) |

(a) To correct errors in debt discount of convertible notes payable related party.

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following is a summary of the impact of these restatements on the Company's Supplemental Disclosure of Cash Flow Information Statement for the fiscal year ended December 31, 2011:

| | December 31, 2011 | | |
|--|------------------------------|---------------------|----------------|
| | As previously reported | Error correction | As restated |
| Non-cash investing and financing activities | | | |
| Beneficial conversion feature | \$741,632 | \$447,024 | (a)\$1,188,653 |
| (a) To correct errors in debt discount of convertible notes payable related party. | | | |

The Error corrections for the year ending December 31, 2011 had no impact on the Statement of Operations and therefore no effect on earnings per share.

2. FIXED ASSETS

Fixed assets consist of the following as of September 30, 2012 and December 31, 2011:

| | 2012 | 2011 |
|---|----------|----------|
| Machinery and equipment | \$55,463 | \$55,463 |
| Furniture and fixtures | 113,635 | 113,635 |
| Computers, equipment and software | 38,105 | 38,105 |
| Leasehold improvements | 12,569 | 12,596 |
| Lab equipment | 115,946 | 115,946 |
| Total | 335,718 | 335,718 |
| Less: accumulated depreciation | 330,944 | 330,001 |
| Fixed assets, net of accumulated depreciation | \$4,774 | \$5,717 |

Depreciation expense for the nine months ended September 30, 2012 and 2011 was \$943 and \$1,304, respectively.

3. INTANGIBLE AND OTHER ASSETS

Patents and trademarks are capitalized at its historical cost and are amortized over their useful lives. As of September 30, 2012, patents and trademarks total \$277,150, net of \$205,670 of accumulated amortization. Amortization expense for the nine months ended September 30, 2012 and 2011 was \$43,039 and \$22,689, respectively.

License and distributor rights (“agreement”) were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of September 30, 2012.

4. UNEARNED REVENUE

Unearned revenue totaling \$179,792 and \$229,792 as of September 30, 2012 and December 31, 2011, respectively relates to a marketing and distribution rights agreement entered into during 2010 for which monies were received and not considered earned. See note 9 “Definitive Agreements”.

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

5. STOCK OPTIONS AND WARRANTS

The following is a summary of option activity during the nine months ended September 30, 2012.

| | Number of Shares | Weighted Average Exercise Price |
|-----------------------------|---------------------|--|
| Balance, December 31, 2011 | 9,980,000 | 0.05 |
| Options granted and assumed | — | — |
| Options expired | 580,000 | 0.4 |
| Options canceled | — | — |
| Options exercised | — | — |
| Balance, September 30, 2012 | 9,400,000 | 0.05 |

As of September 30, 2012, 9,400,000 stock options are exercisable.

Stock warrants -

The following is a summary of warrants activity during the nine months ended September 30, 2012.

| | Number of Shares | Weighted Average Exercise Price |
|------------------------------|---------------------|--|
| Balance, December 31, 2011 | 5,637,451 | 0.10 |
| Warrants granted and assumed | 812,500 | 0.06 |

Edgar Filing: SKINVISIBLE INC - Form 10-Q

| | | |
|-----------------------------|-----------|------|
| Warrants expired | 212,500 | 0.12 |
| Warrants canceled | — | — |
| Warrants exercised | — | — |
| Balance, September 30, 2012 | 6,362,451 | 0.09 |

All warrants outstanding as of September 30, 2012 are exercisable. The warrants issued during 2012 were issued as part of a series of conversions of convertible notes with attached warrants. The warrants issued allow the holder to purchase one share for every two share issued upon conversion.

6. RELATED PARTY TRANSACTIONS

As of September 30, 2012, all related party notes have been extinguished or re-negotiated as convertible notes. See note 8. For the nine months ended September 30, 2011 the Company had no related party transactions.

F-8

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

7. CONVERTIBLE NOTES PAYABLE

| Convertible Notes Payable at consists of the following: | September 30, 2012 | December 30, 2011 |
|---|--------------------------|-------------------------|
| 10% unsecured note payable to an investor, note interest and payment are due on demand. The note could be converted to option rights for Skinvisible, Inc. shares at ten cents per share (\$0.10), these rights expired January 12, 2010. Note is currently in default, no penalties occur due to default. | \$ 60,476 | \$ 62,476 |
| 10% unsecured notes payable to investors, due September 11, 2012. At the investor's option until the repayment date, the note may be converted to shares of the Company's common stock at a fixed price of \$0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of \$0.06 per share for two years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be \$4,664. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of \$4,664 as of September 30, 2012. The beneficial conversion feature is valued under the intrinsic value method. Note is currently is default, no penalties occur due to default. | 14,000 | — |
| 10% unsecured notes payable to investors, due October, 2012. At the written request of the investor's option until the repayment date, the note may be converted to shares of the Company's common stock at a fixed price of \$0.05 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of \$0.07 per share for two years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be \$21,575. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of \$20,551 as of September 30, 2012. The beneficial conversion feature is valued under the intrinsic value method. Interest due to lender can also be converted at a rate of (\$0.05) per share into warrants. | 28,376 | — |
| 8% unsecured notes payable to an investor, due March 13, 2013. At the investor's option until the repayment date, the note and related interest may be converted to shares of the Company's common stock a discount of 58% of the current share price. The Company has determined the value associated with the original issue discount in connection with the notes and interest to be \$55,650. The aggregate original issue discount feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of \$22,179 as of September 30, 2012. The original issue discount feature is valued under the intrinsic value method. | 75,945 | — |
| 8% unsecured notes payable to an investor, due May 15, 2013. At the investor's option until the repayment date, the note and related interest may be converted to shares of the Company's common stock a discount of 58% of the current share price. The Company has determined the | 50,665 | — |

Edgar Filing: SKINVISIBLE INC - Form 10-Q

value associated with the original issue discount in connection with the notes and interest to be \$45,050. The aggregate original issue discount feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of \$7,728 as of September 30, 2012. The original issue discount feature is valued under the intrinsic value method.

9% unsecured notes payable to an investor, due August 1, 2014. At the investor's option until the repayment date, the note and related interest may be converted to shares of the Company's common stock a discount of 90% of the current share price. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be \$19,667. The aggregate original issue discount feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of \$1,616 as of September 30, 2012. The original issue discount feature is valued under the intrinsic value method.

153,836 —

\$383,298 \$62,476

F-9

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

8. CONVERTIBLE NOTES PAYABLE RELATED PARTY

On December 31, 2011, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before December 31, 2010 and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor's option until the repayment date, the note may be converted to shares of the Company's common stock at a fixed price of \$0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of \$0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be \$538,295 for the notes negotiated on December 31, 2010, \$45,557 for the notes negotiated on July 1, 2011 and \$1,123,078 for the notes negotiated December 31, 2011. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of \$365,462 as of September 30, 2012. The beneficial conversion feature is valued under the intrinsic value method.

On June 30, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before July 1, 2011 and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor's option until the repayment date, the note may be converted to shares of the Company's common stock at a fixed price of \$0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of \$0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be \$209,809. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of \$10,401 as of September 30, 2012. The beneficial conversion feature is valued under the intrinsic value method.

9. COMMITMENTS AND CONTINGENCIES

Lease obligations – The Company has operating leases for its offices. Future minimum lease payments under the operating leases for the facilities as of September 30, 2012 are as follows:

2012 17,172

2013 9,601

Rental expense, resulting from operating lease agreements, approximated \$40,434 and \$13,687 for the nine months ended September 30, 2012 and 2011, respectively.

F-10

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

10. DEFINITIVE AGREEMENTS

During the year ended December 31 2011, the Company amended two license agreements previously entered into with RHEI Pharmaceuticals HK Ltd. previously amended October 12, 2010. The amendment canceled what was previously referred to as the “Three Products Agreement” and modified the “DermSafe Agreement” to include license rights to Europe only. The DermSafe Agreement allows for the exclusive manufacturing, marketing and distribution rights to the Companies patent pending hand sanitizer using Chlorhexidine Gluconate as the active ingredient and trademarked DermSafe for Europe. All amounts previously paid for the license agreement were applied to the “DermSafe Agreement”. On July 26, 2011, the DermSafe Agreement was amended, deferring the remaining \$200,000 payment until December 15th, 2011 and all other agreements with RHEI were cancelled, with the option to renegotiate (provided the “Three Products” were not licensed to another company) once the balance payment for DermSafe was received. The cash received has been considered deferred revenue and is amortized over a 5 year period.

As of September 30, 2012, the \$200,000 had not been received. As September 30, 2012, of the cash received of \$300,000, \$145,000 had been amortized and recognized as revenue leaving a balance of \$155,000 as unearned revenue related to this agreement.

11. SUBSEQUENT EVENTS

On October 12, 2012 the company cancelled its agreement with RHEI Pharmaceuticals HK Ltd. due to the cancelation of the agreement Skinvisible will receive the exclusive manufacturing, marketing and distribution rights to the Companies patent pending hand sanitizer using Chlorhexidine Gluconate as the active ingredient and trademarked DermSafe for Europe. The deferred revenue of \$170,000 will be recognized as revenue in the quarter ending December 31, 2012.

On October 15, 2012 the company paid off the outstanding balance of two of the convertible notes held by inventors for a total of \$72,244 which includes a 120% or \$8,500 prepayment penalty on one of the notes. As of the date of payment the balance of the two notes was \$133,660. Accordingly, the remainder of the debt discount in the amount of \$70,793 is to be expensed resulting in a total face value of \$197,404. Accordingly, a gain on extinguishment of debt in the amount of \$125,180 is also to be recorded. When these transactions are off-set the net result is a gain on the settlement of debt in the amount of \$62,867.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Company Overview

We, through our wholly owned subsidiary Skinvisible Pharmaceuticals Inc., are a pharmaceutical research and development (“R&D”) company that has developed and patented an innovative polymer delivery system, Invisicare® and formulated over forty topical skin products which we out-license globally. We were incorporated in 1998, and target an estimated \$80 billion global skincare and dermatology market and a \$30 billion global over-the-counter market as well as other healthcare / medical and consumer goods markets.

With the research and development complete on these forty products and twelve patents issued (technology and product patents), we are ready to monetize our investment. Our business model is to out-license our patented prescription, over-the-counter (“OTC”) and cosmeceutical products featuring Invisicare to established manufacturers and marketers of brands internationally and to maximize its profits from the eight products it has already out-licensed. We have also recently developed a product for Netherton syndrome, for which we are seeking “orphan drug” status in both the United States and Europe. This designation has the potential to be highly lucrative, with more global companies seeing the value of an orphan drug.

Table of Contents

The opportunity for us to license our products has recently increased due to improving market conditions, the need for pharmaceutical companies to access external R&D companies for new products due to their own down-sizing or elimination of internal R&D departments. The demand for our products is enhanced due to the granting of key US and international patents, and the completed development of a number of unique products.

Our Plan for the Next Twelve Months

Our growth strategy is to:

1. Capitalize on the success of current licensees;
2. Increase the value of our current pipeline; and
3. Boost licensing revenues by securing additional licensees globally and develop a robust royalty revenue stream that will finance our future growth.

1. Capitalize On Current Licensees:

We have eight licensees around the globe. Three of these licensees are currently in the marketplace: Avon Products globally, Women's Choice Pharmaceuticals in the United States and Alto Pharmaceuticals in Canada. Additionally, we have five licensees that have products being prepared for launch. We work diligently with our licensees to ensure they have a smooth manufacturing process, ongoing R&D support and marketing feedback.

Avon Products, Inc:

Product: We have a long-term contract with Avon globally for over ten years to provide Invisicare polymer for their long-lasting lipsticks.

Sales: Invisicare polymers are purchased directly from Skinvisible.

Alto Pharmaceuticals:

Product: DermSafe®, long lasting hand sanitizer lotion launched in Canada in Q4 of 2011 for commercial / industrial use

Sales and Royalties: DermSafe has completed its manufacturing in Canada and Health Canada registration requirements and is seeking distributors in the commercial / healthcare marketplace.

They are anticipating an increase in demand in the fourth quarter of 2012, aligned with back to school and the beginning of flu season.

Women's Choice Pharmaceuticals:

Product: ProCort®, long lasting prescription hemorrhoid cream launched in the United States August 2011

Sales and Royalties: ProCort continues to increase sales every t quarter. Skinvisible receives a royalty based on net sales.

On October 23, 2012, we executed a letter agreement (the "Termination Agreement") with RHEI Pharmaceuticals HK Ltd. ("RHEI") to terminate the License Agreement dated June 30, 2010 and its addendums dated July 20, 2011 and October 12, 2010 in relation to the license rights for the product DermSafe in Europe. We received \$300,000 under the License Agreement with a balance of \$200,000 that remained owing. Under the Termination Agreement, in exchange for a waiver of the remaining \$200,000 and all other claims that we might have, RHEI agreed to transfer to us the regulatory approval obtained in Belgium for the product DermSafe. As a further result of the Termination Agreement, the license granted to RHEI to pursue the marketing, manufacture or sale of DermSafe has been cancelled.

Table of Contents

Product Launches for 2012/2013:

We have six additional products licensed to four licensees. These licensees are seeking regulatory approvals in their territories for prescription products and regional registration for over-the-counter products.

Dermal Defense

§ Licensed Safe4Hours® Antibacterial/Antimicrobial Hand Sanitizers (1% Triclosan) for North America to Dermal Defense. Safe4Hours® First Aid Antiseptic & Skin Protectant is a line extension.

Laboratorios Panalab S.A

§ Licensed prescription acne products Adapalene cream for the countries of Argentina, Brazil and Chile for an upfront license fee and royalty.

§ Regional approvals required prior to launch of products which is anticipated to be completed in Q3 of 2012.

Embil Pharmaceuticals Co. Ltd.

§ Licensed two prescription acne products: Clindamycin and Retinoic Acid for the countries of Turkey, Azerbaijan, Kazakhstan, Kyrgyzstan, Turkmenistan, and Uzbekistan, as well as the S.E Asian countries of Indonesia, Malaysia, and the Philippines, for an upfront license fee and royalty.

§ Launch scheduled after regulatory approval in Q1 of 2013.

Mayquest Pharmaceuticals PTY

§ Licensed DermSafe chlorhexidine hand sanitizer for Singapore, Taiwan, Thailand, Indonesia and the Philippines for a license fee and royalty.

§ Received importation approval for DermSafe from Canada to Singapore. Launch pending.

§ Currently seeking distribution partner or sub- licensee to launch the product.

Table of Contents

2. Increasing The Value Of Skinvisible's Pipeline: Clinical Enhancement Of Pipeline

We have a pipeline of over forty products which are available for licensing. Testing is conducted in-house generating proof of concept including release of the active ingredient as well as long term shelf life (stability). Additional studies conducted on specific products including skin sensitivity, toxicity and product efficacy are outsourced to FDA compliant laboratories. These studies are critical in attracting potential licensees. Our clinical strategy is to:

(1) Add new studies for our prescription products. Our clinical strategy is to increase the amount of outsourced studies, specifically for our prescription products. Additional studies including skin penetration and skin irritation studies will add to the integrity and value of our products available for licensing.

(2) Obtain orphan drug status for our Netherton syndrome product. Along with our research and development of products to treat common skin conditions, we have also developed a patent pending product to treat a rare skin condition called Netherton syndrome. This disease is caused by a genetic defect which causes the skin to continually exfoliate, never forming a skin bond. This leaves the patient highly susceptible to infection and dealing with a life-long condition that has no cure.

Our product has shown excellent results in lab studies blocking the enzyme that breaks down the skin and we are seeking "Orphan Drug" designation in both the US and Europe. Applications have been made to both the FDA in the US and the EMA in Europe for approval. Following our presentation to the EMA they requested we complete additional disease-specific studies. The advantages of obtaining Orphan Drug designation is that it provides various incentives including a reduction or elimination of registration and market authorization fees, protocol assistance, and seven years of market exclusivity for the product in the US and ten years in Europe. These incentives are highly attractive to pharmaceutical companies targeting this market. It is anticipated with an orphan drug approval, we will receive a multi-million dollar license fee plus an on-going royalty. We are currently in discussions with potential licensees and we are implementing a pivotal study in the third quarter of 2012 to assist with the approval process.. The study results will then be resubmitted to the both the EMA and FDA for Orphan Drug designation. Our lab studies have shown excellent results so we are positive on the human study.

(3) Seek clinical partnerships which will result in FDA approvals of our prescription products. There are three "Phases" involved in obtaining FDA approval. The completion of Phase 1 and/or Phase 2 will increase the value of the license and royalty fees of our products significantly.

3. Secure Additional Licensees:

We are in discussions with various global, US, Canadian and European based pharmaceutical companies for licenses. These negotiations are at various stages and some are expected to close by the first quarter of 2013.

To facilitate further expansion, we have entered into three agreements with agents knowledgeable and connected in the dermatology market. Two of these agents have existing clients in the United States and Asia.

Results of Operations for the Three and Nine Months Ended September 30, 2012 and 2011

Revenues

Our total revenue reported for the three months ended September 30, 2012 was \$22,920, a decrease from \$31,232 for the same period ended September 30, 2011. Our total revenue reported for the nine months ended September 30, 2012 was \$83,548, a decrease from \$177,502 for the same period ended September 30, 2011. The decrease in revenues for the three and nine months ended September 30, 2012 from the prior periods is attributable to lower sales of polymers to our licensees.

Cost of Revenues

Our cost of revenues for the three months ended September 30, 2012 decreased to \$0, as compared with \$328 for the three months ended September 30, 2011. Our cost of revenues for the nine months ended September 30, 2012 increased to \$1,944, as compared with \$766 for the nine months ended September 30, 2011. The change in our cost of revenues for the three and nine months ended September 30, 2012 from the prior periods is minimal and attributable to sales of polymers.

Gross Profit

Gross profit for the three months ended September 30, 2012 was \$22,920, or approximately 100% of sales. Gross profit for three months ended September 30, 2011 was \$30,904, or approximately 98% of sales. Gross profit for the nine months ended September 30, 2012 was \$81,604, or approximately 97% of sales. Gross profit the nine months ended September 30, 2011 was \$176,736, or approximately 99% of sales.

Table of Contents

Operating Expenses

Operating expenses decreased to \$324,924 for the three months ended September 30, 2012 from \$365,369 for the same period ended September 30, 2011. Our operating expenses for the three months ended September 30, 2012 consisted of \$8,068 in depreciation and amortization and \$316,856 in selling, general and administrative expenses. Our operating expenses for the three months ended September 30, 2011 consisted of \$12,686 in depreciation and amortization and \$352,683 in selling, general and administrative expenses.

Operating expenses decreased to \$1,040,171 for the nine months ended September 30, 2012 from \$895,025 for the same period ended September 30, 2011. Our operating expenses for the nine months ended September 30, 2012 consisted of \$43,982 in depreciation and amortization and \$996,189 in selling, general and administrative expenses. Our operating expenses for the nine months ended September 30, 2011 consisted of \$40,129 in depreciation and amortization and \$854,896 in selling, general and administrative expenses..

Other Expenses

we received other income for the three months ended September 30, 2012 as compared with no other income the same period ended 2011, which was the primary basis for total other income of \$13,098 for the three months ended September 30, 2012 as compared with other expenses of \$27,156 for the prior year period,. We had other expenses of \$55,195 for the nine months ended September 30, 2012 as compared with other expenses of \$70,731 for the prior year period.

Net Loss

We recorded a net loss of \$288,906 for the three months ended September 30, 2012, as compared with a net loss of \$361,621 for the three months ended September 30, 2011. We recorded a net loss of \$1,013,762 for the nine months ended September 30, 2012, as compared with a net loss of \$789,020 for the nine months ended September 30, 2011.

Liquidity and Capital Resources

As of September 30, 2012, we had total current assets of \$102,547 and total assets in the amount of \$384,471. Our total current liabilities as of September 30, 2012 were \$1,796,740. We had a working capital deficit of \$1,694,193 as

of September 30, 2012.

Cash flows used in operating activities was \$175,771 for the nine months ended September 30, 2012. Our net loss of \$1,013,762 was the main component of our negative operating cash flow, offset mainly by amortization of debt discount of \$432,602, and accrued expenses converted to notes in the amount of \$223,868.

Cash flows used by investing activities during the nine months ended September 30, 2012 was \$56,023 as a result of the purchase of fixed and intangible assets.

Cash flows provided by financing activities during the nine months ended September 30, 2012 amounted to \$297,719 and consisted primarily of \$312,900 in proceeds from convertible notes payable.

As of November 2, 2012, we have received \$477,500 in proceeds from the sale of convertible secured promissory notes. From these proceeds, we have repaid two loans totaling \$128,000 plus another \$18,000 to others.

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

Table of Contents

Off Balance Sheet Arrangements

As of September 30, 2012, there were no off balance sheet arrangements.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting policies” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of \$22,132,705 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2012 and December 31, 2011, the Company had not recorded a reserve for doubtful accounts.

Recently Issued Accounting Pronouncements

In January 2010, the FASB (Financial Accounting Standards Board) issued Accounting Standards Update 2010-07 (ASU 2010-07), Not-for-Profit Entities (Topic 958): Not-for-Profit Entities: Mergers and Acquisitions. This amendment to Topic 958 has occurred as a result of the issuance of FAS 164. The Company does not expect the provisions of ASU 2010-07 to have a material effect on the financial position, results of operations or cash flows of the Company.

Table of Contents

In February 2010, the FASB (Financial Accounting Standards Board) issued Accounting Standards Update 2010-08 (ASU 2010-08), Technical Corrections to Various Topics. This amendment eliminated inconsistencies and outdated provisions and provided the needed clarifications to various topics within Topic 815. The amendments are effective for the first reporting period (including interim periods) beginning after issuance (February 2, 2010), except for certain amendments. The amendments to the guidance on accounting for income taxes in reorganization (Subtopic 852-740) should be applied to reorganizations for which the date of the reorganization is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. For those reorganizations reflected in interim financial statements issued before the amendments in this Update are effective, retrospective application is required. The clarifications of the guidance on the embedded derivatives and hedging (Subtopic 815-15) are effective for fiscal years beginning after December 15, 2009, and should be applied to existing contracts (hybrid instruments) containing embedded derivative features at the date of adoption. The Company does not expect the provisions of ASU 2010-08 to have a material effect on the financial position, results of operations or cash flows of the Company.

In February 2010, the FASB issued Accounting Standards Update 2010-09 (ASU 2010-09), Subsequent Events (Topic 855), amending guidance on subsequent events to alleviate potential conflicts between FASB guidance and SEC requirements. Under this amended guidance, SEC filers are no longer required to disclose the date through which subsequent events have been evaluated in originally issued and revised financial statements. This guidance was effective immediately and we adopted these new requirements for the period ended May 31, 2010. The adoption of this guidance did not have a material impact on our financial statements.

In April 2010, the FASB issued ASU No. 2010-17, "Revenue Recognition – Milestone Method (Topic 605): Milestone Method of Revenue Recognition" (codified within ASC 605 – Revenue Recognition). ASU 2010-17 provides guidance on defining a milestone and determining when it may be appropriate to apply the milestone method of revenue recognition for research or development transactions. ASU 2010-17 is effective for interim and annual periods beginning after June 15, 2010. The adoption of ASU 2010-17 is not expected to have any material impact on our financial position, results of operations or cash flows.

In May 2010, the FASB (Financial Accounting Standards Board) issued Accounting Standards Update 2010-19 (ASU 2010-19), Foreign Currency (Topic 830): Foreign Currency Issues: Multiple Foreign Currency Exchange Rates. The amendments in this Update are effective as of the announcement date of March 18, 2010. The Company does not expect the provisions of ASU 2010-19 to have a material effect on the Company's financial position, results of operations or cash flows of the Company.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2012. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2012, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of September 30, 2012, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Table of Contents

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending December 31, 2012: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

We are unable to remedy our controls related to the inadequate segregation of duties and ineffective risk management until we receive financing to hire additional employees. In January 2011, we hired an outsourced controller to improve the controls for accounting and financial reporting.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended September 30, 2012 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

On September 30, 2011, we filed a complaint in the United States District Court for the District of Nevada (the “Court”), against Sunless Beauty, Ltd., Angie Trelstad, TMTA, LLC, and Norvell Skin Solutions, LLC (collectively, the “Defendants”), alleging patent infringement on the Company’s patents: U.S. Patent 6,756,059 B2, 7,674,471 B2, and 6,582,683 B2 (the “Patents”), trademark infringement, misappropriation of trade secrets, and breach of the License Agreement we entered into October 31, 2007 with Sunless Beauty, Ltd. We are seeking, among other things, the following relief from the Court against the Defendants:

Edgar Filing: SKINVISIBLE INC - Form 10-Q

- ◆ For an order declaring that Defendants have infringed one or more claims of the Patents;
- ◆ For an order declaring that Defendants have infringed on the Company's trademarks;
- ◆ For an order declaring that Defendants have willfully misappropriated the Company's trade secrets;
- ◆ A preliminary and permanent injunction against Defendants prohibiting each of them from further infringement of the Patents and the Company's trademarks and trade secrets;
- ◆ For an order declaring that Sunless Beauty Ltd. and Angie Trelstad have breached the License Agreement;
- ◆ An award of damages the Company has suffered by reason of the allegations charged in the complaint;
- ◆ An award to the Company of its costs and attorneys' fees;
- ◆ Such other relief as the Court may deem just and proper.

We have settled with Norvell Skin Solutions, LLC but the case is still open and we are pursuing the action against Sunless Beauty, Ltd., Angie Trelstad and TMTA, LLC.

We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Table of Contents

Item 1A: Risk Factors

A smaller reporting company is not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The information set forth below relates to our issuances of securities without registration under the Securities Act of 1933 during the reporting period which were not previously included in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.

In July 2012, we issued 716,000 restricted shares of our common stock as a result of entering into debt conversion agreements with lenders to convert total principal balances and interest of \$35,800 into equity.

In July of 2012, we issued a consultant a three year warrant to purchase 125,000 shares of our common stock at a strike price of \$0.04 per share.

In August of 2012, we issued a consultant a three year warrant to purchase 100,000 shares of our common stock at a strike price of \$0.04 per share.

On August 31, 2012, we signed a consulting agreement and agreed to issue a one year warrant to purchase 200,000 shares of our common stock at a strike price of \$0.04 per share.

In October 2012, we issued 680,500 shares of our common stock as a result of entering into loan conversion agreements with lenders to convert a total principal balance and interest of \$17,013 into equity. We also issued a two year warrant to the lenders to purchase an aggregate amount of 340,000 shares of common shares at a strike price of \$0.04 per share.

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We

did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

Item 3. Defaults upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits

| Exhibit Number | Description of Exhibit |
|----------------|--|
| 31.1 | <u>Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u> |
| 31.2 | <u>Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u> |
| 32.1 | <u>Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u> |
| 101** | The following materials from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 formatted in Extensible Business Reporting Language (XBRL). |

**Provided
herewith

SIGNATURES

Edgar Filing: SKINVISIBLE INC - Form 10-Q

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Skinvisible, Inc.

Date: November 19, 2012

By: /s/ Terry Howlett

Terry Howlett

Title: Chief Executive Officer, Chief Financial Officer and Director

12

